some thoughts about possible target prices:
The merger will complete sometimes in spring. PacWest had a previous high of roughly 60. Together with CSE there should be value add, and hopefully we can take out the high of 60. That would mean a roughly 30 % premium to the current stock price of 40.
Translating this logic to the CSE price movement wold imply a target price of 18, which is not too far of where CSE traded prior recession.
Sentiment: Strong Buy
21k shares still represent roughly $ 6 Mill; I haven't looked at the cost of the option, but I don't think it's a co-incident that REGN was pinned to 280
Check out these companies and you'll see the potential of CTIX
it's an exciting opportunity. we've got allergies, cholesterol, diabetic macular,
and we haveeylea, a lot happening. we have an enormous talent in the labs and he and his
research team have come up with different opportunities for us, we've got 13 different
products in clinical development and a whole bunch more moving forward which we haven't
talked with you about. excellent. well, i know we're going to in the future. go and listen to this
conference call. you will know why i am still excited even at $300 a share. stay with cramer
Video Transcript -Regeneron CEO: Moreopportunities togrowEylea - CNBC
a group of diseases that are allergic diseases. you get asthma, eczema, nasal poll -- we
hope it's an opportunity, still investigational, a lot of risk, but we're very excited about it.
your senior vice president used the phrase, it brought chills to me. we have seen a
stabilization in your opponent, the share. was it 65, down to 48, why aren't you taking them -
- those bad boys down to 40? why can't -- suddenly your drug, giving their drug away? well,
no, their drug is a lot er and it's used awful label and there are structural changes coming in
compound legislation. meaning that the government may not really like that kind of split up
of the vial. regeneron's view is we're in favor of choice. while patients should have lots of
choices which is good to have a choice, it's good to have a choice, we think there should
only be one quality standard. lots of drugs but only one quality standard. we think that's
what the new law may accomplish and we're looking forward to that. okay. but we have seen
instances where you break open the vial where there's been horrible -- there's been
deaths. well, there's been deaths when people have injected drugs that have compounded.
there has been blindness. this is why we need one quality standard. we need the fda to
regulate this and that's what i think the new compounding legislation if it gets passed will
actually do and it'll make things safer. now, just circle back, it's pertinent now. the diabetic,
you're saying that's ready. that's one of the things -- you're saying they're just waiting.
you're ready to go the moment that thing -- we are ready to go but we still have to go
through the approval process. we've submitted -- what are those people taking right now?
they're using lucentis, it's ahead of us. there's some opportunity out there for people to get
treated. we think our drug could be good, but we have to go through the review process
with the fda.
so they haven't even launched in france, which is a big opportunity.
it's in the early stages outside the united states. but a lot of opportunities to grow in the
united states. okay. now you've got the name for it now. you're talking about a gigantic
lowering of the bad cholesterol drug. others claim they're there. are you -- you on this call
say you were ahead of them and this could be the next big regeneron drug. well,
cholesterol lowering we know is an important part of any strategy to reduce cardiovascular
disease. we think this new class of investigational drugs has the potential to add to that.
there's lots of patients, people who have intolerants, people who can't get to go and there's
room for competitors, we're going as fast as we can, but there's competition. just this past
week, pfizer came out and said they're throwing their hat? . that's what i was going to ask
you about. they said, come on, man, you like this regeneron, we're pfizer. we've got sanofi
which is a great partner. so i think we're going to do pretty well. explain to people how you
can spend a lot of money in r & d like many other companies -- you're being reimbursed by
a large company. sure. we have a very strong partnership where sanofi is spending a lot of
money on our programs. but we said in this call, we're going to spend more of our own
money. after we get this 20% -- we have this 20% responsibility once we have a positive
phase 3. we're going to be spending more of our own money, that's going to go up, but we
have a lot of good things to spend it on. you picked up the cholesterol drug early. i know, i
can't take the darn stat statents. we should get you in one of our clinical trials. do it. i don't
have any with me. however, there's another drug that you can get in on early in terms of
investigational product. that's our drug to treat asthma, hopefully, and eczema. how can
that do both? i thought it was a typo. right. these drugs are linked because they are part of11/5/13 Video Tran
look at regeneron go. here's a biotech stock, one of the four horse men of the big pharma
apocalypse that seems unstoppable to me. just reported this morning the company shot the
lights out. truly stunning numbers. 52-cent earnings beat, 52-cent earnings beat off 1.88
basis. revenues that rose 39.6% year-over-year. biggest beat of the quarter, biggest beat
of the year. what's more, we heard a lot of chatter about regeneron's big block buster
degeneration drug. which could potentially sell the turbo charged growth. what happens,
once again the numbers are phenomenal. linked quarter with management raising their
sales forecast and announcing they've asked the fda for approval for a new indication
diabetic mac -- no matter how well the stock goes, it seems wall street can't get the
collective head around the scale of the opportunity here. stock has given you a 65% gain
since we last spoke to the ceo back in january, may be the best call in the history of mad
money when i initially recommended regeneron trading at $5 back in 2005 after one of our
earliest c.o. interviews. 5,995% gain, if you invested $1,000 in regeneron, it's $60,000. let's
go back into the well with the ceo of regeneron pharmaceuticals, learn more about the
quarter and learn what's next for his business. welcome back to mad money. thanks, jim.
thanks for being here. welcome in on a big day. this was a beautiful play, this conference
call because you started off with the 49% increase. but this diabetic edema, you're saying
570,000 people need and want this drug. well, it's a big opportunity. look, for us, regeneron,
this was a big quarter and it's kind of rare in this business that every aspect of your
business is working. right. we've got a true blockbuster, already done in the first nine
months of the year, $1 billion in the u.s. selling the product well outside of the united states.
you said it's in the early stages the term you used. early stages of this drug. just this week.
we got pricing in franc
i just read the earnings transcript on seeking alpha, and was amazed about the pipeline in R&D and trial phases. REGN reminds me on AMGN 20 years ago. Back then everybody said it's overvalued; they only have one blockbuster and the stock has nothing but to decline. AMGN tripled, quadrupled and then some, making me a ton of money, and I think REGN will do the same. Look for new upgrades or initial covering with target prices of 500 +